James D. Chambers - Concepedia

Author

James D. Chambers

Also Known As

C Bond, Chambers, James D., Huskamp, Haiden A., J Chambers, J. Chambers, J.D. Chambers, JAMES D. CHAMBERS, James Chambers, James D Chambers, James D. Chambers

165

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Tufts Medical Center Tufts University Brunel University of London UCSF Helen Diller Family Comprehensive Cancer Center National Health Council

About

James D. Chambers is an author at Tufts Medical Center specializing in medicine, public health, and health policy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	621
2	Public Health	13	15	537
3	Health Sciences	2	2	152
4	Engineering	1	1	51
5	Cellular Therapies	1	1	23

James D. Chambers

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
The promise of Immuno-oncology: implications for defining the value of cancer treatment Howard L. Kaufman, Michael B. Atkins, Prasun Subedi, Journal for ImmunoTherapy of Cancer	2019	111
Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement Peter J. Neumann, James D. Chambers, Françoise Simon, Health Affairs Drug PolicyRiskbenefit RatioFinancial ProtectionHealth LawHealth Outcomes Are	2011	103
The influence of time horizon on results of cost-effectiveness analyses David D. Kim, Colby Wilkinson, Elle Pope, Expert Review of Pharmacoeconomics & Outcomes Research	2017	93
Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss Neal R. Barshes, James D. Chambers, Joshua T. Cohen, Journal of Vascular Surgery Critical Care ManagementContemporary ManagementLimb ReconstructionPeripheral InterventionPatient Safety	2012	85
Listening to Provenge — What a Costly Cancer Treatment Says about Future Medicare Policy James D. Chambers, Peter J. Neumann New England Journal of Medicine Health ReformFuture Medicare PolicyCancer ManagementEvidence-based MedicineHealth Politics	2011	66
Does Medicare Have an Implicit Cost-Effectiveness Threshold? James D. Chambers, Peter J. Neumann, Martin Buxton Medical Decision Making	2010	62
Specialty Drug Coverage Varies Across Commercial Health Plans In The US James D. Chambers, David D. Kim, Elle Pope, Health Affairs Health Insurance DesignHealth PlansPreventive MedicineDrug MonitoringPublic Health	2018	61
Medicare's Enduring Struggle to Define “Reasonable and Necessary” Care Peter J. Neumann, James D. Chambers New England Journal of Medicine	2012	59
Payer coverage policies for multigene tests Kathryn A. Phillips, Patricia A. Deverka, Julia R. Trosman, Nature Biotechnology Health Insurance ReformEngineeringHealth EconomicsPayer Coverage PoliciesSoftware Testing	2017	51
Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs James D. Chambers, Madison C. Silver, Flora Berklein, Journal of General Internal Medicine Drug RepositioningHealth SciencesHealth PolicyHealth EconomicsPharmacology	2020	49

Page 1